Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06083922
Other study ID # 22-424
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 16, 2023
Est. completion date October 2026

Study information

Verified date October 2023
Source Memorial Sloan Kettering Cancer Center
Contact Hani Hassoun, MD
Phone 646-608-3718
Email hassounh@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 53
Est. completion date October 2026
Est. primary completion date October 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Inclusion criteria for cast nephropathy associated with MM: - Subjects must have a confirmed diagnosis of NDMM as per standard IMWG criteria - Subjects must have measurable disease, defined as meeting at least 1 of the following criteria = 14 days prior to registration: - A monoclonal Immunoglobulin (M-protein) concentration on serum protein electrophoresis (SPEP) of = 0.5 g/dL. - Measurable urinary light chain secretion by quantitative analysis using urine protein electrophoresis (UPEP) of = 200 mg/24 hours. - Involved serum free light chain (FLC) level = 10 mg/dL, provided the serum FLC ratio is abnormal. - eGFR must be <40 ml/min/1.73m2 - Subjects must have histologically confirmed diagnosis of monoclonal gammopathy associated CN by kidney biopsy OR If a kidney biopsy is not available, a percentage of urine albumin excretion (%UAE) < 25 % AND FLC > 50 mg/dL Inclusion criteria for other MGRS associated renal diseases - Histologically confirmed diagnosis of MGRS-associated renal disease by kidney biopsy - Presence of monoclonal gammopathy by serum protein electrophoresis, Immunofixation, or Free Light Chain Assay - Evidence of plasma cell dyscrasia by bone marrow biopsy confirming clonal plasma cell population - eGFR <40 ml/min/1.73m2 or 24h urine total protein > 1gm Inclusion criteria for both cast nephropathy associated with MM and other MGRS associated renal diseases - Subjects must be = 18 years of age at time of registration. - Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 = 14 days prior to registration. - No evidence of unequivocal recent nephrotoxic exposure (NSAIDs, radiocontrast…) - No evidence of obstructive nephropathy by ultrasound - Subjects must have adequate hematology laboratory values within 14 days prior to registration defined by the following: - Neutrophils = 1.0 × 10^9 /L (Patients cannot have received G-CSF or GM-CSF within 1 week of screening or pegfilgrastim within 2 weeks of screening to meet eligibility). - Platelets = 100 × 10^9 /L for run-in and 75 × 10^9 /L for phase II (Note: Platelet support is not permitted to help participants meet eligibility criteria). - hemoglobin = 7.5 g/dL without prior red blood cells [RBC] transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted. - Subjects must have adequate hepatic function laboratory values = 14 days prior to registration: - Aspartate aminotransferase (AST), alkaline phosphatase (AP) or alanine aminotransferase (ALT) = 3 × the upper limit of normal (ULN) - Total bilirubin = 1.5 x ULN except for patients with a history of elevated total bilirubin, such as in Gilbert's. - Hepatic Child-Pugh score at worse A (patients are eligible for the phase 2 part but not for the Run-in-Period of the trial). - Female patients will have to satisfy the following criteria: - Be postmenopausal for at least 1 year Prior to registration visit, OR - Be surgically sterile, OR - If of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR - Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). If patient is female and of childbearing potential, she must have a negative serum beta human chorionic gonadotropin (ß-HCG) test < 14 days prior to registration and consent to ongoing pregnancy testing during the course of the study. - Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following - Practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR - Practice true abstinence when this is in line with the preferred and usual lifestyle of he subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception). - Subjects must have the willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, study procedures, and research procedures. Exclusion Criteria: - MGRS associated with diseases other than plasma cell dyscrasia (e.g. CLL, B-cell neoplasm, Waldenstrom's macroglobulinemia…) - Plasma cell leukemia, AL amyloidosis, or POEMS syndrome. - Treatment with prior drugs aimed at the plasma cell dyscrasia. - Treatment with prior or concurrent investigational agents aimed at the plasma cell dyscrasia. - Female patients who are lactating or have a positive serum pregnancy test during the screening period. - Major surgery = 14 days before registration. - Focal radiation therapy within 14 days prior to registration with the exception of palliative- radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma. - Disease-related central nervous system involvement. - The subject has uncontrolled significant intercurrent illness including, but not limited to, ongoing or active infection. - Clinically significant cardiac disease, including: - Myocardial infarction within 6 months before randomization, or unstable or uncontrolled disease/condition related to or affection cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV) - Uncontrolled cardiac arrhythmia - Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. - Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent. - Concurrent malignancy except for treated non-melanoma skin cancer, cervical carcinoma in situ and low-risk prostate CA being monitored without treatment. - Grade 2 or higher peripheral neuropathy on clinical examination during the screening period. - Chemotherapy = 14 days of registration. - Exposure to an investigational drug (including investigational vaccine) or invasive investigational medical device for any indication within 4 weeks or 5 pharmacokinetic halflives, whichever is longer. - Patients with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal; moderate or severe persistent asthma within the past 2 years. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is <50% of predicted normal - Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate. - Patients who have a contraindication to the use of any form of anticoagulation or antiplatelet agents. - The use of strong CYP3A4 and CYP1A2 inducers or inhibitors will not be allowed while patients are treated on this study. - Patients with Hepatic Child-Pugh score B and C. Note that patients with Hepatic Child-Pugh score A are excluded from the Run-in-Period of the trial - Patient is: - Known history of human immunodeficiency virus (HIV) and those who are seropositive for HIV. - Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR. - Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy). - Vaccination with live attenuated vaccines within 4 weeks of first study agent administration. - Plasmapheresis within 28 days before randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
Days 1, 8 and 15, Cycles 1-8
Bortezomib
Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
Dexamethasone
Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
Daratumumab
Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey
United States Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) Commack New York
United States Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York
United States Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York
United States Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Janssen Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Run-in Phase- Dose-limiting toxicity (DLT) rates Any participant in the run-in-phase who received at least = 75% of the planned doses of the combination regimen in cycle one will be evaluated for DLTs using NCI-CTCAE. 2 years
Primary Phase II (Cohort A) best renal response For patients with a decreased eGFR <50mL/min/1.73 m2 with or without significant proteinuria (UTP>0.5 gm/24h) at presentation, Assessment of renal response will be based on both the IMWG criteria for patient with decreased eGFR and the amyloid criteria for patients with proteinuria. 2 years
Primary Pilot study (Cohort B) best renal response For patients with a decreased eGFR <50mL/min/1.73 m2 with or without significant proteinuria (UTP>0.5 gm/24h) at presentation, renal response will be assessed using IMWG renal response criteria 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1